Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | STS | P08842 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1857032 | 1.00 | MEN1 (0.50) | MEN1KMT2AALDH1A1MAPTSTS | |
| SCHEMBL1867513 | 0.92 | ALDH1A1 (0.55) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL3616198 | 0.88 | KMT2A (0.51) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL1867710 | 0.88 | KMT2A (0.51) | MEN1KMT2AALDH1A1MAPTHPGD | |
| SCHEMBL2326004 | 0.84 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPTUSP30 | |
| SCHEMBL2326008 | 0.84 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1MAPTUSP30 | |
| SCHEMBL971486 | 0.83 | KDM2B (0.60) | MEN1KMT2AALDH1A1MAPTSTS | |
| SCHEMBL5475032 | 0.83 | ALDH1A1 (0.59) | MEN1KMT2AALDH1A1MAPTUSP30 | |
| SCHEMBL971485 | 0.83 | KDM2B (0.60) | MEN1KMT2AALDH1A1MAPTSTS | |
| SCHEMBL969184 | 0.83 | ALDH1A1 (0.59) | MEN1KMT2AALDH1A1MAPTUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580823-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| EP-2074108-B3 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2581366-A1 | Renin Inhibitors | Vitae Pharmaceuticals, Inc. (US) | 2013-04-17 | — | — | EP | disclosed |
| EP-2074108-B1 | RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2012-09-06 | — | — | US | disclosed |
| US-8198453-B2 | Piperidine renin inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| EP-2081927-B1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-08-17 | — | — | EP | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090318501-A1 | Piperidine derivatives as renin inhibitors | VITAE PHARMACEUTICALS, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090312369-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS , INC. | 2009-12-17 | — | — | US | disclosed |
| EP-1966139-A1 | ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007070201-A1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | MEN1 2467/4885KMT2A 2255/4885ALDH1A1 1416/4885 |
| US-20120225906-A1 | PIPERIDINE RENIN INHIBITORS | ACE, PEPD, DNPEP | MEN1 3669/4885KMT2A 2534/4885ALDH1A1 711/4885 |
| US-20090312369-A1 | Renin Inhibitors | ACE, REN, DNPEP | MEN1 2144/4885KMT2A 3751/4885ALDH1A1 1307/4885 |
| US-20090318501-A1 | Piperidine derivatives as renin inhibitors | ACE, DNPEP, PEPD | MEN1 3790/4885KMT2A 2774/4885ALDH1A1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.